Table 2.

Summary table comparing cohort characteristics and results regarding age stratification in the present study and TAILORx.

	The recent TAILORx [1; 2; 3]	The present study
Research category	Prospective trial	Retrospective research
Main analysis set	9,719 eligible patients with follow–up information	49,539 eligible patients with follow–up information
Clinicopathological feature	HR+/ HER2–/ N0	HR+/ HER2–/ N0
Registration time	April 2006 – October 2010	January 2010 – December 2015
RS distribution	0–10 17% (1619/9719)	0–10 22.5% (11164/49539)
	11–25 69% (6711/9719)	11–25 64.1% (31731/49539)
	26–100 14% (1389/9719)	26–100 13.4% (6644/49539)
Summary of the results regarding to age stratification	A low proportion of distant recurrence at 9 years with endocrine therapy alone if the RS was 0–15, irrespective of age	The mean RS were different among five age groups (≤35, 36–50, 51–65, 66–80, and > 80 years of age)
	Age > 50 with a RS of 0–25, and ≤ 50 with a RS of 0–15, endocrine therapy was non-inferior to chemoendocrine therapy	The most common age group was 51–65 years, followed by 36–50 years, 66–80 years, ≤35 years, and > 80 years
	Age ≤ 50, chemotherapy was associated with some benefit for women who had a RS of 16–25	The percentage of low–risk RS (0–10) patients increased with age
	Age ≤ 50 with high clinical risk and RS (11–25) who received endocrine therapy alone, and those RS (26–100) who received chemoendocrine therapy, the distant recurrence rate at 9 years exceeded 10%	The percentage of intermediate–risk RS (11–25) patients decreased with age except for the group of 36–50 years, which has the highest rate of intermediate risk RS
	Age ≤ 50 and RS (11–25), endocrine therapy was noninferior to chemoendocrine therapy at 9 years if clinical risk was low; while chemotherapy was associated with benefit if clinical risk was high	The group aged ≤ 35 years has the greatest rate of high–risk RS
	Age > 50, endocrine therapy was noninferior to chemoendocrine therapy in the cohort with a RS of 11–25, regardless of clinical risk category	The proportion of receiving chemotherapy decreases with age in all RS risk categories
	Age ≤ 50, distant recurrence rate at 9 years were very low among women with a RS of 0–10, irrespective of clinical–risk category	Age ≤ 35 with RS of 26–100 had the highest chemotherapy receipt rate, while age > 80 with RS of 0–10 had the lowest chemotherapy receipt rate
	The chemotherapy benefit was most evident at 45 years of age in premenopausal women and waned at younger and older ages and with menopause	Overall survival was benefited by chemotherapy only in the age group of 66–80 years of age with intermediate- and high-risk RS
	There were significant interactions between chemotherapy treatment and age (≤50 vs. 51 to 65 vs. >65 years) for invasive disease–free survival (P = 0.03) and for freedom from recurrence of breast cancer at a distant or local–regional site (P = 0.02) but not at a distant site (P = 0.12)	Age > 80, the chemotherapy seemed to do more harm than good